First results from the RxPONDER trial suggest postmenopausal women with HR+, HER2- breast cancer with one to three positive nodes and a recurrence score of 25 or lower can safely skip adjuvant chemotherapy. The international trial, presented at the virtual 2020 San Antonio Breast Cancer Symposium, comprised 5,083 patients with stage 2-3 breast cancer randomised ...
RxPONDER trial shows women can safely skip adjuvant chemo
By Mardi Chapman
16 Dec 2020